ReviewCardiology and therapy2020
Diagnosis of Transthyretin Amyloid Cardiomyopathy.
Review in Cardiology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.ESC heart failure · 2022Pooled it
- Physiologically relevant forms of Tc- and Re-pyrophosphate radioactive tracers and the basis of their transthyretin amyloid sensitivity.Scientific reports · 2026Article
- Electrocardiographic Features in Transthyretin Cardiac Amyloidosis.Diagnostics (Basel, Switzerland) · 2025Article
- [World journal of nuclear medicine · 2025Article
- Challenges in the approach to a patient with aortic stenosis and cardiac amyloidosis with ATTR mutation associated with negative scintigraphy - A case report.American heart journal plus : cardiology research and practice · 2024Article
- Prevalence and characteristics of patients with incidental cardiac uptake on bone scintigraphy.Journal of cardiovascular imaging · 2024Article
- Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Article
- Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Hereditary transthyretin amyloid cardiomyopathy.Singapore medical journal · 2023Article
- Disease progression in cardiac morphology and function in heart failure: ATTR cardiac amyloidosis versus hypertensive left ventricular hypertrophy.Heart and vessels · 2022Article
- Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis.Orphanet journal of rare diseases · 2022Article
- Healthcare resource use of patients with transthyretin amyloid cardiomyopathy.ESC heart failure · 2022Article
- Healthcare resource use associated with the diagnosis of transthyretin amyloidosis cardiomyopathy.Health science reports · 2022Article
- Implementing a Machine-Learning-Adapted Algorithm to Identify Possible Transthyretin Amyloid Cardiomyopathy at an Academic Medical Center.Clinical Medicine Insights. Cardiology · 2022Article
- Myocardial Work Does Not Have Additional Diagnostic Value in the Assessment of ATTR Cardiac Amyloidosis.Journal of clinical medicine · 2021Article
- Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021.Arquivos brasileiros de cardiologia · 2021Article
- Article
- From Clinical Clues to Final Diagnosis: The Return of Detective Work to Clinical Medicine in Cardiac Amyloidosis.Frontiers in cardiovascular medicine · 2021Article
- Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy.Clinical cardiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transthyretin amyloid cardiomyopathy (ATTR-CM) continues to be an easily overlooked, life-threatening, yet treatable cause of heart failure. Furthermore, its elusive diagnosis leads to late or misdiagnosis. As therapeutic advancements such as tafamidis usher in a promising new era in the management of ATTR-CM, the need for disease awareness and efficient diagnostic evaluation is crucial. With newer inexpensive imaging modalities and techniques, such as longitudinal strain imaging, T1 mapping on cardiac magnetic resonance imaging, and cardiac scintigraphy, the diagnosis of ATTR-CM no longer requires invasive evaluation with tissue biopsy. Here, the authors review current diagnostic tools to help clinicians diagnose ATTR-CM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.